TXGMEDIUM SIGNALOPERATIONAL10-K

TXG demonstrated substantially improved operational performance with meaningful revenue growth and significantly reduced losses.

The company's financial trajectory appears to have reversed course with strong top-line expansion alongside disciplined cost management that dramatically narrowed operating losses. The reduced capital expenditure suggests either completion of a major investment cycle or more conservative spending, while the substantial improvement in net losses indicates progress toward profitability.

Comparing 2026-02-13 vs 2025-02-13View on EDGAR →
FINANCIAL ANALYSIS

TXG's financial performance improved meaningfully across key metrics, with revenue growing substantially while operating and net losses were dramatically reduced, suggesting enhanced operational efficiency. The company maintained a strong balance sheet position with current assets expanding modestly to $684.5 million, though current liabilities also increased to $153.5 million. Capital expenditures were roughly halved to $5.9 million, indicating either completion of major investments or a shift to more conservative spending, while working capital components like accounts receivable and inventory both declined significantly.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-93.1%
$476K$33K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Net Income
P&L
+76.2%
-$182.6M-$43.5M

Net income grew 76.2% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+68.7%
-$194.6M-$61.0M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Revenue
P&L
+68.1%
$146.3M$245.9M

Strong top-line growth of 68.1% — accelerating demand or successful expansion into new markets.

Capital Expenditure
Cash Flow
-52.1%
$12.4M$5.9M

Capex reduced 52.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Accounts Receivable
Balance Sheet
-46.5%
$87.9M$47.0M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Inventory
Balance Sheet
-32.2%
$83.1M$56.3M

Inventory drawn down 32.2% — strong sell-through or deliberate destocking; watch for supply constraints.

Current Liabilities
Balance Sheet
+30.5%
$117.6M$153.5M

Current liabilities surged 30.5% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+17.5%
$208.5M$245.0M

Liabilities increased 17.5% — monitor debt-to-equity ratio and interest coverage.

Current Assets
Balance Sheet
+17.1%
$584.4M$684.5M

Current assets grew 17.1% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-02-13
PRIOR — 2025-02-13
ADDED
As of January 31, 2026, the registrant had 117,673,382 shares of Class A common stock, $0.00001 par value per share, outstanding and 10,078,872 shares of Class B common stock, $0.00001 par value per share, outstanding.
Our revenue was $642.8 million and $610.8 million for the years ended 2025 and 2024, respectively, representing a year-over-year increase of 5%.
We generated net losses of $43.5 million and $182.6 million for the years ended 2025 and 2024, respectively.
In the years ended December 31, 2025 and 2024, we sold 1,007 and 1,073 instruments and 424,000 and 357,100 consumable reactions, respectively.
The Chromium portfolio enables high-throughput analysis of individual biological components.
+7 more — sign up free →
REMOVED
As of January 31, 2025, the registrant had 108,245,008 shares of Class A common stock, $0.00001 par value per share, outstanding and 14,056,833 shares of Class B common stock, $0.00001 par value per share, outstanding.
s expectations regarding our plans, objectives, goals, beliefs, business strategies, results of operations, financial position, sufficiency of our capital resources, business outlook, future events, business conditions, key business metrics and key factors affecting our performance, gross margin trends, expected future investments including anticipated capital expenditures, anticipated size of market opportunities and our ability to capture them, expected uses, performance and benefits of our products and services, business trends and other information.
Our revenue was $610.8 million and $618.7 million for the years ended 2024 and 2023, respectively, representing a year-over-year decrease of 1%.
We generated net losses of $182.6 million and $255.1 million for the years ended 2024 and 2023, respectively.
In the years ended December 31, 2024 and 2023, we sold 1,073 and 1,336 instruments and 357,100 and 347,000 consumable reactions, respectively.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →